Free weekly newsletter
Get the free weekly contract digest
The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Halozyme Therapeutics Offers to Acquire Germany-Based Evotec for ~$2 Billion
Nov 17, 2024•over 1 year ago
Contract Type
partnership
San DiegoManufacturingBiotechnologyHealth CarePharmaceuticalBiopharmaDescription
Halozyme Therapeutics announced its non-binding proposal to acquire Evotec SE for 2.0 billion euros, representing a premium of 109% to Evotec’s undisturbed share price. The proposed partnership aims to diversify and extend Halozyme's revenue and EBITDA growth, enable ongoing investments in Evotec’s early-stage programs and new technologies, and significantly expand and diversify Halozyme’s revenue and EBITDA over the next decade.
Related People
Suggested for you
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months